Search Medical Condition
Please enter condition
Please choose location from dropdown

Richmond, Texas Clinical Trials

A listing of Richmond, Texas clinical trials actively recruiting patient volunteers.

RESULTS

Found (80) clinical trials

Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism

Subjects with pulmonary embolism with a RV/LV >0.9 and hemodynamically stable who meet all eligibility criteria and sign informed consent will be randomized to one of 4 treatment groups (see below). 48 hours after the start of treatment, a repeat CTA will be obtained and a RV/LV obtained. Thereafter, subjects ...

Phase N/A

2.72 miles

Learn More »

A Study to Assess the Effects of RO6889450 in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms

This study investigates the effects of RO6889450 on the negative symptoms associated with schizophrenia and schizoaffective disorder.

Phase

4.8 miles

Learn More »

Real-life Effectiveness of Vortioxetine in Depression

Worldwide Major Depressive Disorder (MDD) has significant negative personal, societal and economic consequences. Vortioxetine (Brintellix) is a new antidepressant authorized since 2013. Despite evidence generated from clinical trials which demonstrate that vortioxetine is an efficacious, well-tolerated antidepressant, there is a need to determine the effectiveness of vortioxetine in real life ...

Phase N/A

5.9 miles

Learn More »

Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)

This is a non-interventional, prospective, multi-center observational cohort study. Patients at community-based behavioral health clinics will be enrolled and evaluated by health care professionals (e.g., psychiatrists) according to the standard of care. All patients will be followed for approximately 12 months from their enrollment visit.

Phase N/A

5.9 miles

Learn More »

This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia

The primary objective of this Phase II exploratory trial is to provide Proof of Concept (PoC) data to assess the effect on cognition of oral once daily administration of BI 425809 given for 12 weeks in patients with schizophrenia on stable antipsychotic treatment and adjunctive Computerized Cognitive Training (CCT).

Phase

5.9 miles

Learn More »

INtervention Study In overweiGHT Patients With COPD

Symptoms of chronic obstructive pulmonary disease (COPD) and high body mass index (BMI) overlap. The investigators are trying to find out if a program proven to help people lose a modest amount of weight and increase their physical activity will improve COPD symptoms for those with a high BMI. The ...

Phase N/A

7.22 miles

Learn More »

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE )

This is a blinded and placebo-controlled study of topical testosterone replacement therapy (TRT) in symptomatic hypogonadal men with increased risk for cardiovascular (CV) disease.

Phase

7.75 miles

Learn More »

A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis

The objective of this study is to evaluate efficacy and safety of risankizumab using a new formulation compared with placebo for treatment of moderate to severe plaque psoriasis.

Phase

8.49 miles

Learn More »

A Study to Evaluate Risankizumab in Adult and Adolescent Subjects With Moderate to Severe Atopic Dermatitis

The purpose of this study is to assess the safety and efficacy of risankizumab for the treatment of moderate to severe atopic dermatitis (AD) in adult and adolescent subjects.

Phase

8.49 miles

Learn More »

Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer

PRIMARY OBJECTIVES: I. To compare invasive disease-free survival (IDFS) of patients with triple-negative breast cancer (TNBC) who have either >= 1 cm residual invasive breast cancer and/or positive lymph nodes (> ypN+) after neoadjuvant chemotherapy randomized to receive 1 year of MK-3475 (pembrolizumab) adjuvant therapy compared to no MK-3475 (pembrolizumab), ...

Phase

8.87 miles

Learn More »